Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Beinaglutide

Route injection

Class GLP-1 RA

Mechanism GLP-1 receptor agonist

Sources

registry, as of 2023-03-17Stale

https://clinicaltrials.gov/study/NCT05005741

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.. Overall status UNKNOWN. Phases PHASE4. Lead sponsor Second Xiangya Hospital of Central South University. Enrollment 120. Conditions Diabetes Mellitus, Type 2; Overweight or Obesity. This study is a multi-center, open label, randomized controlled trial that main purpose of this study is to evaluate the differences of glucose control and weight loss between Beinaglutide and Dulaglutide in type 2 diabetes with overweight or or Obesity.

ClinicalTrials.gov NCT05005741 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05005741

trial to investigate the differences of glucose control and weight loss between two GLP-1 receptor agonist, Beinaglutide and Dulaglutide, in type 2 diabetes with overweight or Obesity. The study comprises the 0-2 weeks of screening period and the 16-week intervention period. 120 patients according to the inclusion/

NCT05005741 description or intervention text

Studies

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Registry NCT05005741

Phase Phase 4

Enrollment 120

Start 2021-05-01

Primary completion 2023-12-31

Study completion 2023-12-31

Beinaglutide

Regimen once weekly

Weeks 16

Population Diabetes Mellitus, Type 2; Overweight or Obesity

Dulaglutide

Regimen once weekly

Weeks 16

Population Diabetes Mellitus, Type 2; Overweight or Obesity